In the original article, there was a mistake in
Figure 1C,
Supplementary Figure S2,
Figure 3B, and
Figure 4as published:
(1) In Figure 1C and Supplementary Figure S2, the IHC images of IGF1R were erroneously used as the results of Collagen IV. The corrected IHC images of Collagen IV were displayed as below.
(2) In Figure 3B, WB gels related to SGLT2 and IGF1R should be annotated according to Con-DA-DN. The corrected Figure 3B was displayed as below.
(3) In Figure 4A, the annotation of WB gel for Nephrin and α-SMA was reversed. The corrected Figure 4A was displayed as below.
(4) In Figures 4B,D, the annotation of the bar for Nephrin and α-SMA was reversed. The corrected Figure 4 was displayed as below.
(5) Supplemenary Figures S10–S12 are added as the raw data of Figures 3, 4 and Supplemenary Figure S9.
FIGURE 1
FIGURE 3
FIGURE 4
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
diabetic nephropathy, sodium-glucose cotransporter-2 inhibitors, insulin-like growth factor-1 receptor, podocyte, epithelial-mesenchymal transition
Citation
Guo R, Wang P, Zheng X, Cui W, Shang J and Zhao Z (2022) Corrigendum: SGLT2 inhibitors suppress epithelial-mesenchymal transition in podocytes under diabetic conditions via downregulating the IGF1R/PI3K pathway. Front. Pharmacol. 13:1074294. doi: 10.3389/fphar.2022.1074294
Received
19 October 2022
Accepted
23 November 2022
Published
22 December 2022
Volume
13 - 2022
Edited and reviewed by
Zhiyong Guo, Second Military Medical University, China
Updates
Copyright
© 2022 Guo, Wang, Zheng, Cui, Shang and Zhao.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jin Shang, fccshangj2@zzu.edu.cn; Zhanzheng Zhao, zhanzhengzhao@zzu.edu.cn
This article was submitted to Renal Pharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.